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Study Protocol Objective
To perform a meta-analysis of case control and cohort studies which measure Epstein-Barr virus (EBV) seropositivity in patients with Rheumatoid Arthritis (RA) compared to healthy controls.
Criteria for consideration of studies Inclusion criteria Studies
-Case control or cohort studies recording EBV seropositivity data -Studies using any assay for EBV antibodies (VCA, EBNA-1, EA) may be included. 
Exclusion criteria -Studies which only measure IgM to EBV antigens (detecting recent EBV infection) -Non-human studies

Search strategy
-A search for studies relevant to rheumatoid arthritis and EBV will be carried out using MEDLINE and EMBASE.
-A combination of specific MeSH terms or EMBASE headings and text words will be used to identify relevant studies.
-Reference lists of relevant articles will be hand searched to identify any further relevant studies
Method of Review
-Non-human studies, studies without a sample population, and case reports will be excluded.
-Abstracts of all possibly relevant articles will be read by two researchers. Discrepancies over which full texts to obtain will be resolved by discussion -Full texts of all case-control and cohort studies relating RA and EBV will be obtained and the quality of studies assessed by two researchers. Doubts over inclusion will be resolved by discussion.
Data extraction
The following data will be extracted using a standard form -Year of Study 
Data analysis
The prevalence of EBV positive serology in subjects with autoimmune disease will be compared with that of age matched healthy controls.
-Results with different antibodies (e.g. anti-ENBA 1 IgG and anti-VCA IgG) will be analysed separately -Age matched studies will be assessed separately -Studies using community controls will be assessed separately
Statistical analysis
Following data extraction the following statistical analysis will be performed using Review 
